Meir Medical Center
clalit.co.ilTotal trials
395
Active
27
Phase 3
13
Total enrollment
80,818
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone | — | — | — | — | — | 1 | |
| local tranexamic acid | — | — | — | — | — | 1 | |
| Eltroxin administration | — | — | — | — | — | 1 | |
| PGE2 | — | — | — | — | — | 1 | |
| administration of vitamin C | — | — | — | — | — | 1 | |
| Automated urinary output collection system group | — | — | — | — | — | 1 |
Next readouts
- 2025-07
- 2026-01
- 2026-02-01
- 2027-02-01
- 2027-12-31
- 2028-05-01
Top conditions
- Infertility9
- Obesity9
- Pregnancy6
- Childhood Obesity4
- Food Allergy4
- Vitamin D Deficiency4
- Healthy4
- Crohn's Disease3
Frequently asked questions about Meir Medical Center
- How many clinical trials does Meir Medical Center have on ClinicalTrials.gov?
- Meir Medical Center is listed as the lead sponsor on 395 clinical trials in ClinicalTrials.gov, 27 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Meir Medical Center's trials are in Phase 3?
- 13 of Meir Medical Center's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does Meir Medical Center focus on?
- Meir Medical Center's most-studied conditions on ClinicalTrials.gov are Infertility, Obesity, Pregnancy, Childhood Obesity, Food Allergy.
- When are Meir Medical Center's next clinical trial readouts?
- Meir Medical Center has 6 upcoming primary-completion readouts tracked here; the soonest is “Local Tranexamic Acid During Vaginal Hysteractomy to Reduce Blood Loss”, expected around 2025-07.